This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
BioNumerik Pharmaceuticals, Inc.
Drug Names(s): BNP7787, Dimesna
Description: Tavocept (BNP7787) is a chemoprotecting agent aimed at preventing certain side effects associated with taxane and platinum drugs, which are widely used for treating cancer. Tavocept is thought to be a free radical scavenger and to inhibit or mediate tubulin polymerization (tubulin forms microtubules, which are the basis for a cells cytoskeleton and are involved in a number of processes), which is thought to be a cause of nerve toxicity.
BioNumerik holds exclusive rights to Tavocept for all territories outside of Japan. BioNumerik has granted KI Pharmaceuticals, a joint venture formed by BioNumerik and ASKA, the exclusive right to develop, market, distribute and sell Tavocept in Japan.
BioNumerik/ASKA and Takeda
In October 2004, Takeda entered into an alliance agreement with BioNumerik Pharmaceuticals to market Tavocept in the United States and Canada. Under the terms of the alliance agreement, Takeda will market Tavocept following regulatory approval in the U.S. and Canada. The alliance agreement provides that BioNumerik and Takeda will equally share any profits from sales of Tavocept in the United States and Canada. In October 2006, this alliance agreement was terminated.
In March 2006, ASKA Pharmaceutical and Takeda announced today that both parties and BioNumerik entered into a license agreement for Tavocept in Japan. Under the agreement, an exclusive right to market Tavocept in Japan...See full deal structure in Biomedtracker
Partners: Lantern Pharma, Inc
Additional information available to subscribers only: